Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Nicolas

Showing results (471-480 of 499) with videos related to

Pageof 50
Sort By:
Synapse (New York, N.Y.)|December 28, 1999
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive statesM J Millan, A Newman-Tancredi, V Audinot, et al.
The British Journal of Nutrition|February 15, 2001
5,10-methylenetetrahydrofolate reductase common mutations, folate status and plasma homocysteine in healthy French adults of the Supplementation en Vitamines et Mineraux Antioxydants (SU.VI.MAX) cohortA Chango, G Potier De Courcy, F Boisson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 15, 2019
Cholecystokinin 2 Receptor Agonist <sup>177</sup>Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a StudyChristof Rottenburger, Guillaume P Nicolas, Lisa McDougall, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 18, 2001
Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterizationM J Millan, D Cussac, G Milligan, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 22, 1999
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profileM J Millan, A Gobert, A Newman-Tancredi, et al.
Journal of Neuroendocrinology|November 8, 2025
Systematic review and meta-analysis of the efficacy and safety of [<sup>177</sup>Lu]Lu-edotreotide ([<sup>177</sup>Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumorsRichard P Baum, Julia G Fricke, Tristan Ruhwedel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 6, 2024
First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([<sup>161</sup>Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileumJulia Fricke, Frida Westerbergh, Lisa McDougall, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 18, 2023
A phase I/II study of the safety and efficacy of [<sup>177</sup>Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumoursDamian Wild, Henning Grønbæk, Shaunak Navalkissoor, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 23, 2025
First-in-human administration of [<sup>61</sup>Cu]Cu-NODAGA-LM3 and head-to-head comparison with [<sup>68</sup>Ga]Ga-DOTA-TOC PET/CT as part of the phase I/II COPPER PET in NET studyGuillaume P Nicolas, Manuel Alejandre Lafont, Lisa McDougall, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 18, 2000
S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidineM J Millan, A Dekeyne, A Newman-Tancredi, et al.
Pageof 50

Showing results (471-480 of 499) with videos related to

Sort By:
Pageof 50
Synapse (New York, N.Y.)|December 28, 1999
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive statesM J Millan, A Newman-Tancredi, V Audinot, et al.
The British Journal of Nutrition|February 15, 2001
5,10-methylenetetrahydrofolate reductase common mutations, folate status and plasma homocysteine in healthy French adults of the Supplementation en Vitamines et Mineraux Antioxydants (SU.VI.MAX) cohortA Chango, G Potier De Courcy, F Boisson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 15, 2019
Cholecystokinin 2 Receptor Agonist <sup>177</sup>Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a StudyChristof Rottenburger, Guillaume P Nicolas, Lisa McDougall, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 18, 2001
Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterizationM J Millan, D Cussac, G Milligan, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 22, 1999
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profileM J Millan, A Gobert, A Newman-Tancredi, et al.
Journal of Neuroendocrinology|November 8, 2025
Systematic review and meta-analysis of the efficacy and safety of [<sup>177</sup>Lu]Lu-edotreotide ([<sup>177</sup>Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumorsRichard P Baum, Julia G Fricke, Tristan Ruhwedel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 6, 2024
First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([<sup>161</sup>Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileumJulia Fricke, Frida Westerbergh, Lisa McDougall, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 18, 2023
A phase I/II study of the safety and efficacy of [<sup>177</sup>Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumoursDamian Wild, Henning Grønbæk, Shaunak Navalkissoor, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 23, 2025
First-in-human administration of [<sup>61</sup>Cu]Cu-NODAGA-LM3 and head-to-head comparison with [<sup>68</sup>Ga]Ga-DOTA-TOC PET/CT as part of the phase I/II COPPER PET in NET studyGuillaume P Nicolas, Manuel Alejandre Lafont, Lisa McDougall, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 18, 2000
S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidineM J Millan, A Dekeyne, A Newman-Tancredi, et al.
Pageof 50